Orbital Labs Test Uniform Drug Crystal Growth

Varda's three October 2026 spacecraft carry research experiments, with commercial drug-crystal production still in the testing stage.

Updated on Nov. 8, 2026 in Space

Small white re-entry capsule under a deployed orange and white parachute drifting over a pale desert plain beneath a faint curved horizon of atmosphere.
Varda Space Industries launched three spacecraft in October 2026 carrying unmanned mini-laboratories to run microgravity drug-crystal experiments, with samples returned to Earth by capsule. AI Illustration. Upload story photo >

Live Poll

Do you think space-made medicines will improve healthcare for ordinary people?

Varda Space Industries launched three spacecraft in October 2026, two on October 1 and one on October 20, carrying unmanned mini-laboratories that run microgravity experiments. The development is shipped and operational: Varda has already returned a capsule from orbit, but the October launches are still in progress.

Why it matters

Varda's launches extend a pattern of in-orbit manufacturing moving from demonstration toward routine use, with capsules designed to return samples to Earth. The company's plan for seven missions in 2027 and ten in 2028 signals an attempt to shift from occasional flights to a regular cadence.

The spacecraft are similar in size to a standard washing machine and orbit at about 480 km. One carries crystals of a candidate anticancer drug, while the other two test heat shield materials and navigation systems for the return trip to Earth.

The players

Varda Space Industries

A private company that builds returnable capsules to run drug-crystal and materials experiments in orbit, and has already retrieved a capsule from space.

Space Forge

A United Kingdom company that launched a manufacturing satellite in June 2025 and generated plasma in orbit in December 2025, with a goal of demonstrating its full manufacturing-to-Earth-recovery process before 2030.

The details

Each spacecraft carries unmanned mini-laboratories that run experiments in orbit. Once the experiments conclude, a capsule containing the samples detaches, re-enters the atmosphere, and deploys a parachute to land on Earth. The rationale rests on microgravity, the condition of near-weightlessness in orbit: on Earth, gravity causes heavier components to sink or mix unevenly during crystal formation, producing irregular crystals, whereas microgravity lets drug crystals grow more uniformly, which can alter dissolution speed and shelf life.

Timeline

  1. February 2024: Varda recovered its first capsule, which contained ritonavir crystals.

  2. June 2025: Space Forge, a United Kingdom company, launched a manufacturing satellite.

  3. December 2025: Space Forge generated high-temperature plasma in orbit.

  4. October 1, 2026: Varda launched two spacecraft.

  5. October 20, 2026: Varda launched a third spacecraft.

The Tech Race

Varda's February 2024 recovery of a ritonavir-crystal capsule was the milestone that its October 2026 launches build on. Space Forge's manufacturing satellite and orbital plasma work place the United Kingdom company in the same effort to make in-orbit production returnable.

For now, the experiments are research-stage and not a consumer product, so the practical effect is on drug developers who could eventually use microgravity-grown crystals. Timelines for when such drugs or materials reach patients have not been announced.

The takeaway

Watch whether Varda's October 2026 capsules return intact and whether its seven 2027 missions launch on schedule. Those outcomes will show whether returnable orbital manufacturing is moving from demonstration to a repeatable service.

What happens next

Varda plans seven space missions in 2027 and ten in 2028, and Space Forge targets demonstrating its full manufacturing-to-Earth-recovery process before 2030.

Further reading

For the broader context of commercial work in orbit, explore more Space coverage.

Source note: This article includes information reported by 조선일보.

Live Poll

Do you think space-made medicines will improve healthcare for ordinary people?